Comparative Pharmacology
Head-to-head clinical analysis: CORTALONE versus ELOCON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTALONE versus ELOCON.
CORTALONE vs ELOCON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response, and regulate metabolism.
Elocon (mometasone furoate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to the glucocorticoid receptor, leading to increased synthesis of lipocortins that inhibit phospholipase A2, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene formation. It also suppresses cytokine production and inflammatory cell migration.
10-40 mg orally once daily in the morning; for acute exacerbations, up to 60 mg/day divided into 2-4 doses.
Apply a thin film to affected skin area once daily. Use no more than 45 g per week.
None Documented
None Documented
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life approximately 5-7 hours after topical application. Systemic half-life is short, limiting systemic accumulation with topical use.
Primarily renal (60-70% as unchanged drug), with 10-20% biliary/fecal.
Primarily hepatic metabolism; metabolites excreted renally and in feces. Approximately 60% of a topical dose is excreted in urine as metabolites, 30% in feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid